Press Release: European Medicines Agency recommends first-in-class medicine for treatment of cystic fibrosis

Author (Corporate)
Series Title
Series Details EMA/CHMP/343656/2012 (25.5.12)
Publication Date 25/05/2012
Content Type

The European Medicines Agency, on 25 May 2012, recommended Kalydeco (ivacaftor), an orphan-designated medicine, for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the cystic fibrosis transmembrane regulator (CFTR) gene.
Source Link http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001520.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/343656/2012 (25.5.12): European Medicines Agency recommends first-in-class medicine for treatment of cystic fibrosis http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/05/WC500127800.pdf
Subject Categories
Countries / Regions